Section 'Sub' Navigation:
Dr. David S. Adler
Clinical Research, Pharmaceutics, Therapeutic Outcomes
David S. Adler, Pharm.D.
Professor of Clinical Pharmacy
Associate Dean for Academic Affairs
Skaggs School of Pharmacy and Pharmaceutical Sciences Health Sciences Clinical Professor, Non-Salaried Department of Family and Preventative Medicine
Research Summary: Clinical, Pharmaceutics, MTM
Dr. Adler’s research interests are in clinical research and practice with a focus on management of chronic drug therapy including bioavailability and therapeutic equivalency of drugs with a narrow therapeutic index, drug elimination in renal failure and dialysis, clinical applications of point-of-care testing and medication therapy management (MTM). Dr. Adler maintains a clinical practice in anti-coagulation therapy and management in Coumadin Clinics at UCSD Medical Center through Internal Medicine and the San Diego Veteran's Administration Medical Center through the Division of Hematology.
B.A. in Biochemistry (1966) UC Berkeley; Pharm.D. (1970) UCSF; ASHP Residency in Pharmacy Practice (1971) UCSF.
Awards and Honors:
Fellow, California Society of Health-System Pharmacists (1993); Pharmacist of the Year, California Society of Health-System Pharmacists (1987); Outstanding Contribution Award, Boehringer-Mannheim Corp., Science Partner (1995, 1997); Distinguished Service Award, California Society of Health-System Pharmacists (1993); Long’s Award for Excellence in Teaching, UCSF School of Pharmacy (2000, 2002); Academy of Clinical Scholars, UCSD Health Sciences, School of Medicine/School of Pharmacy and Pharmaceutical Sciences (2003 - present).
Vice Chair, Department of Clinical Pharmacy, UCSF School of Pharmacy (1975- 1996); Associate Director, Department of Pharmacy, University of California Medical Center, San Diego, (1979-2002); Coordinator, UCSD/UCSF ASHP Clinical Pharmacy Residency Program (1977-1992); President, Chair Board of Directors, Chair House of Delegates California Society of Health Systems Pharmacists (1982-1984); Chairman, Planning Committee, Western States Conference for Residents and Preceptors (1986-87); Director of Curriculum UCSD SSPPS (2000-2002); Co-Chair Pfizer and Biogen-Idec Clinical Oncology Fellowship Programs (2007- present).
- Concepts in Pharmacy Practice (202A).
- Contemporary Topics in Pharmacology (SPPS 218A/B).
- Therapeutics (SPPS 212B).
- Pharmacogenomics (SPPS 219).
- Advanced Practice Ambulatory Care Anticoagulation Clinic (SPPS 401 A/B).
- Pharmacy Law and Ethics (SPPS 204).
Key Contributions to Pharmaceutical Sciences
- Removal of phenytoin by hemodialysis, model for efficacy of evaluating dialysis for treatment of toxicity.
- Solubility of phenytoin in intravenous solutions.
- Clinical equivalency and bioavailability of sodium warfarin from multiple sources.
Selected Recent Publications (view more)
- Adler et al. (1975). Hemodialysis of Phenytoin in a Uremic Patient. Clin. Pharmacol. Ther. 18:65-69.
- Martin et al. (1977). Removal of Phenytoin by Hemodialysis in Uremic Patients. J.A.M.A. 238:1750- 1753.
- Pfeifle et al. (1981). Phenytoin Solubility in Three Intravenous Solutions. Am. J. Hosp. Pharm. 38:358- 362.
- Weibert et al. (1989). Evaluation of a Capillary Whole-Blood Prothrombin Time Measurement System. Clin. Pharm. 8:864-867.
- Ansell et al (1991). Measurement of the Activated Partial Thromboplastin Time from a Capillary (fingerstick) Sample of Whole Blood. A New Method for Monitoring Heparin Therapy. Amer. J. Clin. Path. 95:222-227.
- Weibert et al. (2000). A Randomized, Crossover Comparison of Warfarin Products in the Treatment of Chronic Atrial Fibrillation. Annals of Pharmacotherapy 34:981-988.
- Hirsch et al (2014). Primary Care-Based, Pharmacist- Physician Collaborative Medication-Therapy Management of Hypertension: A Randomized, Pragmatic Trial. Clin Ther 36:1244-54
Potential Collaborative Programs with the Pharmaceutical Industry
- Thirty-five years of experience in clinical practice and translational research.
- Developing novel practice models and diverse approaches to medication therapy management, to improve safe and effective drug therapy treatments.